 High risk acute leukemia patients except t9;22q34; q11 cytogenetic abnormalities. received interferon α-2b after prophylactic DLI at day 30-60 after unmanipulated blood and marrow transplantation. The end points were safety, leukemia-free survival, and immunologic response. Following time is 12 months. 